Начало › Рак на белия дроб с недребноклетъчен тип › Калифорния › San Diego
Клинични проучвания за Рак на белия дроб с недребноклетъчен тип в San Diego, CA
48 проучвания за Рак на белия дроб с недребноклетъчен тип търсят участници в обекти в и около San Diego (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Набиране на участнициФаза 2/3
- UC San Diego Health - Moores Cancer Center /ID# 278836, La Jolla · на 11 мили
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Набиране на участнициФаза 3
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Набиране на участнициФаза 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · на 11 мили
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- University of San Diego Moores Cancer Center, La Jolla · на 11 мили
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Набиране на участнициФаза 3
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Набиране на участнициФаза 1
- University of California San Diego Moores Cancer Center, San Diego
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Набиране на участнициФаза 1
- ALX Center 9, La Jolla · на 11 мили
A Study of PHN-012 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- PHN-012-001 Site, San Diego
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Набиране на участнициФаза 2
- University of California at San Diego, La Jolla · на 11 мили
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 3
- UC San Diego McGrath Outpatient Pavilion - Hillcrest, San Diego
- UC San Diego Medical Center - Hillcrest, San Diego
- UCSD Medical Center - Rancho Bernardo, San Diego
- и още 3
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Набиране на участнициНаблюдателно проучване
- University of California San Diego, La Jolla · на 11 мили
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- Moores Cancer Center at UC San Diego Health, La Jolla · на 11 мили
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Набиране на участнициФаза 2
- University of California San Diego Health, La Jolla · на 11 мили
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Набиране на участнициФаза 1/2
- Scripps Clinic Torrey Pines (Scripps Cancer Center), La Jolla · на 11 мили
- Scripps Green Hospital, La Jolla · на 11 мили
- Scripps Shiley Pavilion, La Jolla · на 11 мили
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Kaiser Permanente San Diego Mission Road, San Diego
Pan-tumor MRD Study
Набиране на участнициНаблюдателно проучване
- Medical Oncology Associates of San Diego (MOASD), San Diego
- Medical Oncology Associates of San Diego, San Diego
Intratumoral N17350 in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Scripps Clinic Torrey Pines - La Jolla, San Diego
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Набиране на участнициФаза 2/3
- University Of California - San Diego Moores Cancer Center, La Jolla · на 11 мили
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Набиране на участнициФаза 3
- Clinical Study Site, San Diego
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Набиране на участнициНаблюдателно проучване
- University of California, San Diego, La Jolla · на 11 мили
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- UCSD Moores Cancer Center, La Jolla · на 11 мили
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Набиране на участнициФаза 1
- University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla · на 11 мили
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Набиране на участнициФаза 3
- Research Site, San Diego
- Research Site, La Jolla · на 11 мили
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Набиране на участнициФаза 1
- University of California - San Diego Moores Cancer Center, La Jolla · на 11 мили
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Набиране на участнициФаза 3
- Sharp Memorial Hospital ( Site 9544), San Diego
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Набиране на участнициФаза 1
- University of California San Diego, Moores Cancer Center, San Diego
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, San Diego
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Набиране на участнициФаза 2
- Kaiser Permanente San Diego Mission Road, San Diego
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- UC San Diego Medical Center - Hillcrest, San Diego
- California Protons Cancer Therapy Center, San Diego
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Набиране на участнициФаза 1/2
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- University of California, San Diego; Moores Cancer Center, San Diego
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Набиране на участнициФаза 1/2
- University of California, San Diego Moores Cancer Center, San Diego
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- UCSD Moores Cancer Center, La Jolla · на 11 мили
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Набиране на участнициФаза 1
- University of California San Diego Moores Cancer Center, San Diego
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Набиране на участнициФаза 3
- Research Site, San Diego
- Research Site, La Jolla · на 11 мили
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2/3
- Kaiser Permanente-San Diego Zion, San Diego
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Набиране на участнициФаза 2
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Набиране на участнициФаза 2
- University of California San Diego Moores Cancer Center, La Jolla · на 11 мили
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Набиране на участнициФаза 1/2
- University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla · на 11 мили
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Набиране на участнициФаза 1/2
- Research Site, La Jolla · на 11 мили
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Набиране на участнициФаза 1/2
- VA San Diego Healthcare System, San Diego, CA, San Diego
Retifanlimab and Ruxolitinib In Solid Malignancies
Набиране на участнициФаза 1/2
- University of California, San Diego Moores Cancer Center, La Jolla · на 11 мили
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, La Jolla · на 11 мили
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Набиране на участнициФаза 1/2
- UCSD Moores Cancer Center, La Jolla · на 11 мили
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Набиране на участнициФаза 1
- UC San Diego Moores Cancer Center, La Jolla · на 11 мили
Проучвания за Рак на белия дроб с недребноклетъчен тип в други градове
- Houston, TX145 проучвания
- New York City, NY121 проучвания
- Arlington, VA104 проучвания
- Nashville, TN97 проучвания
- Boston, MA90 проучвания
- Los Angeles, CA87 проучвания
- St. Louis, MO73 проучвания
- Chicago, IL61 проучвания
- Baltimore, MD60 проучвания
- San Antonio, TX59 проучвания
- Columbus, OH57 проучвания
- Washington, DC55 проучвания
Други проучвания в San Diego
- Рак на гърдата41 проучвания
- Рак (всички видове)32 проучвания
- Рак на простатата31 проучвания
- Метастатичен рак30 проучвания
- Колоректален рак25 проучвания
- Рак на яйчниците24 проучвания
- Рак на панкреаса24 проучвания
- Рак на белия дроб23 проучвания
- Затлъстяване23 проучвания
- Сърдечна недостатъчност23 проучвания
- Депресия21 проучвания
- Меланом18 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.